Karam JA - Search Results

1

Epidemiology of Renal Cell Carcinoma: 2022 Update.

Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP. Bukavina L, et al. Among authors: karam ja. Eur Urol. 2022 Nov;82(5):529-542. doi: 10.1016/j.eururo.2022.08.019. Epub 2022 Sep 10. Eur Urol. 2022. PMID: 36100483 Review.

2

Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.

Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Shariat SF, et al. Among authors: karam ja. Eur Urol. 2005 Sep;48(3):424-31. doi: 10.1016/j.eururo.2005.04.034. Eur Urol. 2005. PMID: 15963628

3

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Karam JA, et al. Urology. 2007 Sep;70(3):482-6. doi: 10.1016/j.urology.2007.05.009. Urology. 2007. PMID: 17905101

4

New circulating biomarkers for prostate cancer.

Bensalah K, Lotan Y, Karam JA, Shariat SF. Bensalah K, et al. Among authors: karam ja. Prostate Cancer Prostatic Dis. 2008;11(2):112-20. doi: 10.1038/sj.pcan.4501026. Epub 2007 Nov 13. Prostate Cancer Prostatic Dis. 2008. PMID: 17998918 Review.

5

Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81.

Shariat SF, Karam JA, Karakiewicz PI. Shariat SF, et al. Among authors: karam ja. Eur Urol. 2009 Jan;55(1):250-2. doi: 10.1016/j.eururo.2008.09.037. Eur Urol. 2009. PMID: 20050019 No abstract available.

6

Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma.

Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Karam JA, et al. J Urol. 2010 Nov;184(5):1882-7. doi: 10.1016/j.juro.2010.06.109. Epub 2010 Sep 17. J Urol. 2010. PMID: 20846689 Free PMC article.

7

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.

Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Karam JA, et al. J Urol. 2011 Feb;185(2):439-44. doi: 10.1016/j.juro.2010.09.086. Epub 2010 Dec 17. J Urol. 2011. PMID: 21167518 Free PMC article.

8

Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.

Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Karam JA, et al. Eur Urol. 2011 Apr;59(4):619-28. doi: 10.1016/j.eururo.2010.11.043. Epub 2010 Dec 8. Eur Urol. 2011. PMID: 21167632

9

The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.

Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. Cost NG, et al. Among authors: karam ja. Eur Urol. 2011 Jun;59(6):912-8. doi: 10.1016/j.eururo.2011.02.032. Epub 2011 Feb 23. Eur Urol. 2011. PMID: 21367518

10

The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.

Karam JA, Wood CG. Karam JA, et al. Hematol Oncol Clin North Am. 2011 Aug;25(4):753-64. doi: 10.1016/j.hoc.2011.05.002. Hematol Oncol Clin North Am. 2011. PMID: 21763966 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page